Quantum Computing Stock Gains Pharma Customer With First Drug Discovery Deal
- INmune Bio and Quantum Computing Inc. announced a past collaboration to use QCi's Dirac-3S quantum optimization machine with AI and data analytics to search for new disease indications for XPro, an investigational Alzheimer's treatment.
- This partnership gives Quantum Computing Inc. its first paying customer in the pharmaceutical and biotechnology sector, opening a real test case for applying its room temperature quantum systems to complex drug discovery problems.
- The next area of attention is how Quantum Computing Inc.'s first commercial pharmaceutical collaboration might influence the existing investment narrative around quantum hardware.
Quantum Computing Investment Narrative Recap
To own Quantum Computing, you need to believe its photonic quantum hardware and AI products can shift from small R&D-style contracts to repeatable commercial deployments in computing, networking and security. The INmune Bio agreement fits that thesis by putting QCi’s Dirac-3S system into a real drug discovery workflow, but it is still one engagement in a business that reports modest quarterly revenue.
In the short term, the key catalyst remains evidence that pilots in pharma, data centers or telecom convert into scalable offerings that lift revenue above the current contract-driven base. The biggest risk stays the same: operating expenses run in the millions each quarter while revenue is small, so heavy upfront investment could widen losses if demand does not materialize as hoped.
The INmune Bio collaboration is the clearest operational proof point tied to this story. It is QCi’s first commercial customer in pharmaceutical and biotechnology markets and uses the Dirac-3S entropy quantum optimization machine on real clinical and biomedical datasets alongside AI. The work also has defined options for follow-on stages if XPro development progresses.
For investors tracking catalysts, this project directly tackles two issues. It tests whether QCi’s room temperature systems add measurable value versus conventional analytics, and it builds a repeatable quantum discovery process that could apply to other disease programs. Execution risk is still high, given QCi’s small revenue base and rising costs, but this contract gives a concrete operational benchmark to watch rather than a purely theoretical pipeline.
Quantum Computing's current analyst story points to revenue of $243.4 million and earnings of $1.8 million by 2029. That setup assumes yearly revenue growth of 283.0% and an earnings swing of about $41.5 million, from a loss of $39.7 million today to the forecast profit level.
Uncover why Quantum Computing's fair value indicates a 168% potential upside to its current price, before that discount to expectations starts to close.
Exploring Other Perspectives
One alternate angle focuses on capacity risk rather than new contracts. The most cautious analysts worried that Fab 2 might stay underused and previously pencilled in revenues of about US$72.6 million and earnings of roughly US$5.4 million by 2029. That is far more restrained than the consensus story. This new INmune Bio collaboration could eventually shift those expectations, so treat it as a prompt to compare multiple narratives, not a final answer.
Explore 3 other Quantum Computing fair value estimates, including one that suggests it could be worth just $10.00!
Form Your Own Verdict
Don't just follow the ticker; dig into the data and build a conviction that's truly your own.
- A great starting point for your Quantum Computing research is our analysis highlighting 1 key reward that could impact your investment decision.
- See our latest analysis for Quantum Computing. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Quantum Computing's overall financial health at a glance.
Looking For More Quantum Computing Investment Ideas?
If Quantum Computing's story has you thinking about where else emerging technologies and strong fundamentals might align, it can help to scan a wider field of opportunities using the Simply Wall St Screener.
- For investors who care most about quality at a discount, use the screener to search for 32 high quality undervalued stocks that pair robust fundamentals with prices that look out of sync with underlying strength.
- If capital preservation and steadier risk profiles matter more to you than chasing the highest upside, narrow your watchlist to 32 resilient stocks with low risk scores that score well on resilience and consistency.
- When you want sturdier finances backing the story, filter for companies from the list of solid balance sheet and fundamentals (25 results) and focus on businesses with cleaner leverage and healthier cash positions.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com